Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Reviews in Medical Virology · 2026
DOI: 10.1002/rmv.70172 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Reviews in Medical Virology, 2026. Verfasst von Taimoor Tahir und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Kuwait Teaching Hospital, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Metformin, COVID-19 Drug Treatment, Hypoglycemic Agents. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Metformin has been shown to reduce hospitalisation and symptom duration among adults with COVID‐19, but the effect has not been studied. We conducted this meta‐analysis to assess the efficacy and safety of metformin in patients with COVID‐19. Randomized controlled trials (RCTs) comparing metformin with placebo in COVID‐19 were identified through major databases through November 2025. We performed statistical analyses using RevMan 5.4, employing the random‐effects model, along with Risk Ratio (RR) and Mean Difference (MD) as the effect measures. Our meta‐analysis of four RCTs showed that metformin did not significantly reduce the composite outcome of hospitalisation, emergency department (ED) visits, or death, compared with placebo (RR 0.60, 95% CI 0.40–0.90.21). The incidence of all‐cause mortality (RR 1.00; 95% CI 0.06–15.91) and serious adverse events (RR 2.86; 95% CI 0.76–10.76) was also comparable between the two groups. Our meta‐analysis, with low to moderate certainty, found that metformin may provide modest benefit in reducing hospitalisation, ED visits, or mortality in patients with COVID‐19 without an association with increased serious adverse events. However, these findings should be interpreted cautiously, given the limited number of trials, low event rates, and clinical heterogeneity across studies. Further large RCTs are needed before metformin can be considered for use in COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Kuwait Teaching Hospital, Peshawar, Pakistan.
- Department of Medicine, Nishtar Medical University, Multan, Pakistan.
- Department of Medicine, Fatima Memorial College of Medicine and Dentistry, Lahore, Pakistan.
- Department of Medicine, Punjab Medical College, Faisalabad, Pakistan.
- Department of Medicine, Fauji Foundation Hospital, Rawalpindi, Pakistan.
- Department of Medicine, People's University of Medical and Health Sciences, Nawabshah, Pakistan.
ORCID-Profile: Muhammad Abubakr Siddique, Asma'a Munasar Ali Alsubari, Muhammad Ehsan, Jibran Ikram
Zitieren
APA
Tahir, T., Siddique, M. A., Ijaz, K., Nadeem, H., Rehman, A., Khan, S., Tarar, A. H., Lajwanti, Zafar, M. A. S., Raja, F., Jafar, U., Alsubari, A. M. A., Ehsan, M., & Ikram, J. (2026). Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70172
Vancouver
Tahir T, Siddique MA, Ijaz K, Nadeem H, Rehman A, Khan S, et al. Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70172
BibTeX
@article{Tahir2026,
author = {Tahir, Taimoor and Siddique, Muhammad Abubakr and Ijaz, Khadija and Nadeem, Hania and Rehman, Abdur and Khan, Sameen and Tarar, Amna Humayun and Lajwanti and Zafar, Muhammad Ahmad Shujja and Raja, Fatima and Jafar, Uzair and Alsubari, Asma'a Munasar Ali and Ehsan, Muhammad and Ikram, Jibran},
title = {Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Reviews in Medical Virology},
year = {2026},
doi = {10.1002/rmv.70172}
}
EUVIMED